var data={"title":"Isoproterenol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Isoproterenol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6408?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=isoproterenol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Isoproterenol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=isoproterenol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Isoproterenol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184870\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Isuprel</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184910\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Beta<sub>1</sub>/Beta<sub>2</sub> Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184872\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Patients may exhibit dose-dependent vasodilation due to unopposed beta<sub>2</sub>-agonism elicited by isoproterenol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bradyarrhythmias, AV nodal block:</b> Continuous IV infusion: Usual range: 2 to 10 mcg/minute; titrate to patient response (AHA [Neumar 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Brugada syndrome with electrical storm (off-label use):</b> IV bolus: Initial: 1 to 2 mcg, followed by a continuous infusion of 0.15 to 0.3 mcg/minute for 1 day; may repeat sequence if ventricular tachycardia/fibrillation recurs (Watanabe 2006; Zipes 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Cardiogenic shock due to bradycardia (off-label use):</b> Continuous IV infusion: 2 to 10 mcg/minute (AHA [van Diepen 2017])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Provocation during tilt table testing for syncope (off-label use):</b> Continuous IV infusion: Initial: 1 mcg/minute; increase as necessary based on response; maximum dose: 5 mcg/minute (Benditt 1996; Brignole 2004). <b>Note:</b> Timing of initiation and dose adjustment during test may be institution-specific.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Provocation of ventricular arrhythmias in suspected arrhythmogenic right ventricular cardiomyopathy (off-label use):</b> 45 mcg/minute for 3 minutes (regardless of initial heart rate) followed by evaluation for arrhythmia. <b>Note:</b> Perform test after withdrawing beta-blockers, calcium channel blockers, and other antiarrhythmic agents for at least 5 half-lives (Denis 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Torsade de pointes (refractory) (off-label use): </b>Continuous IV infusion: Usual range: 2 to 10 mcg/minute; titrate to patient response (AHA [Neumar 2010])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184892\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=isoproterenol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Isoproterenol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Patients may exhibit dose-dependent vasodilation due to unopposed beta<sub>2</sub>-agonism elicited by isoproterenol.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bradycardia, severe; AV nodal block:</b> Limited data available: Infants, Children, and Adolescents: Continuous IV infusion: 0.05 to 0.5 mcg/kg/minute; titrate to effect; doses as high as 2 mcg/kg/minute may be needed in some patients (Park 2014); usual adult range: 2 to 10 mcg/minute (AHA [Neumar 2010])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184873\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160042\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160043\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184850\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Isuprel: 0.2 mg/mL (1 mL, 5 mL) [contains disodium edta]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.2 mg/mL (1 mL, 5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184835\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184853\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: IV infusion administration requires the use of an infusion pump.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472666\" class=\"block uica drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 1 mg in 100 mL (10 <b>mcg</b>/mL), 1 mg in 500 mL (2 <b>mcg</b>/mL), <b>or</b> 4 mg in 250 mL (16 <b>mcg</b>/mL) of D<sub>5</sub>W or NS</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14472667\" class=\"block uicp drugH1Div\"><span class=\"drugH1\">Usual Infusion Concentrations: Pediatric</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>IV infusion:</b> 20 <b>mcg</b>/mL </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184851\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Manufacturer&rsquo;s labeled indications (see <b>&quot;Note&quot;</b>): Mild or transient episodes of heart block that do not require electric shock or pacemaker therapy; serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation); cardiac arrest until electric shock or pacemaker therapy is available; bronchospasm during anesthesia; adjunct to fluid and electrolyte replacement therapy and other drugs and procedures in the treatment of hypovolemic or septic shock and low cardiac output states (eg, decompensated heart failure, cardiogenic shock)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> The use of isoproterenol in advanced cardiac life support (ACLS) has largely been supplanted by the use of other adrenergic agents (eg, epinephrine and dopamine). The use of isoproterenol for bronchospasm during anesthesia and cardiogenic, hypovolemic, or septic shock is no longer recommended. See <i>Off-label Use</i> for more appropriate, yet unlabeled, uses.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726429\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bradycardia (significant hemodynamic compromise); Cardiogenic shock; Provocation during tilt table testing for syncope; Provocation of ventricular arrhythmias in suspected arrhythmogenic right ventricular cardiomyopathy; Torsades de pointes; Beta-blocker overdose; Electrical storm associated with Brugada syndrome; Temporary control of bradycardia in denervated heart transplant patients unresponsive to atropine; Ventricular arrhythmias due to AV nodal block</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184919\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Isuprel&reg; may be confused with Disophrol&reg;, Isordil&reg;</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184842\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Adams-Stokes syndrome, angina pectoris, flushing, hypertension, hypotension, pallor, palpitations, paradoxical bradycardia (with tilt table testing), tachyarrhythmia, ventricular arrhythmia, ventricular premature contractions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Dizziness, headache, nervousness, restlessness, seizure (Adams-Stokes)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Diaphoresis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypokalemia, increased serum glucose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, pulmonary edema</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184856\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Angina, pre-existing ventricular arrhythmias, tachyarrhythmias; cardiac glycoside intoxication</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184839\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, coronary artery disease); may increase myocardial oxygen demand resulting in ischemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Diabetes: Use with caution in patients with diabetes mellitus; may transiently increase blood glucose levels.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Distributive shock: Avoid use in patients with distributive shock; may reduce systemic vascular resistance (SVR) further resulting in hemodynamic compromise.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism; may induce thyroid storm in susceptible individuals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Elderly: Use with caution in the elderly.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sulfites: Contains sulfites; may cause allergic reaction in susceptible individuals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: Use with extreme caution; not currently a treatment of choice. Excessive or prolonged use may result in decreased effectiveness.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299548\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of COMT</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184844\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8578&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">COMT Inhibitors: May decrease the metabolism of COMT Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalational Anesthetics: May enhance the arrhythmogenic effect of Isoproterenol.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Linezolid: May enhance the hypertensive effect of Sympathomimetics. Management: Reduce initial doses of sympathomimetic agents, and closely monitor for enhanced pressor response, in patients receiving linezolid.  Specific dose adjustment recommendations are not presently available.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tedizolid: May enhance the hypertensive effect of Sympathomimetics. Tedizolid may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Theophylline Derivatives: Isoproterenol may decrease the serum concentration of Theophylline Derivatives. <b> Exceptions: </b>Dyphylline.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184846\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7732005\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted by the manufacturer. Use of isoproterenol may interfere with uterine contractions at term (Mahon 1967).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20680182\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if isoproterenol is present in breast milk. The manufacturer recommends that caution be exercised when administering isoproterenol to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184848\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">ECG, heart rate, respiratory rate, arterial blood gas, arterial blood pressure, CVP; serum glucose, serum potassium, serum magnesium</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184838\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Stimulates beta<sub>1</sub>- and beta<sub>2</sub>-receptors resulting in relaxation of bronchial, GI, and uterine smooth muscle, increased heart rate and contractility, vasodilation of peripheral vasculature</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F184855\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: IV: Immediate </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: IV: 10-15 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Via conjugation in many tissues including hepatic and pulmonary </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 2.5-5 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (primarily as sulfate conjugates)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323236\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Isoproterenol HCl Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg/mL (1 mL): $1,320.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Isuprel Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.2 mg/mL (1 mL): $1,766.94</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038663\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Aleudrina (ES);</li>\n      <li>Antasthmin (AT);</li>\n      <li>Asmadren (NO);</li>\n      <li>Bellasthman Medihaler (DE);</li>\n      <li>Dyspnoesan (NL);</li>\n      <li>Erydin (DK);</li>\n      <li>Euspiran (CZ);</li>\n      <li>Ingelan (AT, DE);</li>\n      <li>Isolin (IN);</li>\n      <li>Isomel (IE);</li>\n      <li>Isomenyl (JP);</li>\n      <li>Isoprenalin (NO, SE);</li>\n      <li>Isoprenalina Cloridrato (IT);</li>\n      <li>Isoprenalinhydrochlorid-Braun (LU);</li>\n      <li>Isuprel (EG, HU, KW, LU);</li>\n      <li>Isuprel HCl (BE, FR, HK, KR, TH);</li>\n      <li>Isuprel Inj (AU, NZ);</li>\n      <li>Isupril (JO);</li>\n      <li>Kattwilon N (DE);</li>\n      <li>Medihaler-Iso (GB, LU, NL, PT);</li>\n      <li>Min-I-Jet Isoprenaline (GB);</li>\n      <li>Novodrin (DE);</li>\n      <li>Proterenal (AR);</li>\n      <li>Proternol L (TW);</li>\n      <li>Saventrine (AE, FI, GB, GR, IE, QA, SG);</li>\n      <li>Sedansol Iso (JP);</li>\n      <li>Sooner (JP)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Almquist A, Goldenberg IF, Milstein S, et al, &ldquo;Provocation of Bradycardia and Hypotension by Isoproterenol and Upright Posture in Patients With Unexplained Syncope,&rdquo; <i>N Engl J Med</i>, 1989, 320(6):346-51.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoproterenol-drug-information/abstract-text/2913492/pubmed\" target=\"_blank\" id=\"2913492\">2913492</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benditt DG, Ferguson DW, Grubb BP, et al, &ldquo;Tilt Table Testing for Assessing Syncope. American College of Cardiology,&rdquo; <i>J Am Coll Cardiol</i>, 1996, 28(1):263-75.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoproterenol-drug-information/abstract-text/8752825/pubmed\" target=\"_blank\" id=\"8752825\">8752825</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brignole M, Alboni P, Benditt DG, et al, &ldquo;Guidelines on Management (Diagnosis and Treatment) of Syncope &ndash; Update 2004,&rdquo; <i>Europace</i>, 2004, 6(6):467-537.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoproterenol-drug-information/abstract-text/15519256/pubmed\" target=\"_blank\" id=\"15519256\">15519256</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"24970294\"></a>Denis A, Sacher F, Derval N, et al. Diagnostic value of isoproterenol testing in arrhythmogenic right ventricular cardiomyopathy. <i>Circ Arrhythm Electrophysiol</i>. 2014;7(4):590-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoproterenol-drug-information/abstract-text/24970294/pubmed\" target=\"_blank\" id=\"24970294\">24970294</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122 (18 Suppl 3):640-56.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoproterenol-drug-information/abstract-text/20956217/pubmed\" target=\"_blank\" id=\"20956217\">20956217</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7296791\"></a>Keren A, Tzivoni D, Gavish D, et al, &quot;Etiology, Warning Signs and Therapy of Torsade de Pointes. A Study of 10 Patients,&quot; <i>Circulation</i>, 1981, 64(6):1167-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoproterenol-drug-information/abstract-text/7296791/pubmed\" target=\"_blank\" id=\"7296791\">7296791</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahon WA, Reid DW, and Day RA, &quot;The <i>in vivo</i> Effects of Beta Adrenergic Stimulation and Blockade on the Human Uterus at Term,&quot; <i>J Pharmacol Exp Ther</i>, 1967, 156(1):178-85.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoproterenol-drug-information/abstract-text/6023594/pubmed\" target=\"_blank\" id=\"6023594\">6023594</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7732979\"></a>Morillo CA1, Klein GJ, Zandri S, Yee R. Diagnostic accuracy of a low-dose isoproterenol head-up tilt protocol. <i>Am Heart J</i>. 1995;129(5):901-906.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoproterenol-drug-information/abstract-text/7732979/pubmed\" target=\"_blank\" id=\"7732979\">7732979</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. <i>Circulation.</i> 2010;122(18 suppl 3):7297-67. doi: 10.1161/CIRCULATIONAHA.110.970988.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Park, MK. <i>Park's Pediatric Cardiology for Practitioners</i>. 6th ed. Philadelphia, PA: Elsevier Health Sciences; 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11233951\"></a>Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. <i>Med clin North Am</i>. 2001;85(2):321-341.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoproterenol-drug-information/abstract-text/11233951/pubmed\" target=\"_blank\" id=\"11233951\">11233951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"28923988\"></a>van Diepen S, Katz JN, Albert NM, et al; American Heart Association Council on Clinical Cardiology; Council on Cardiovascular and Stroke Nursing; Council on Quality of Care and Outcomes Research; Mission: Lifeline. Contemporary management of cardiogenic shock: a scientific statement from the American Heart Association. <i>Circulation</i>. 2017;136(16):e232-e268. doi:10.1161/CIR.0000000000000525.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoproterenol-drug-information/abstract-text/28923988/pubmed\" target=\"_blank\" id=\"28923988\">28923988</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Watanabe A, Fukushima Kusano K, Morita H, et al, &quot;Low-Dose Isoproterenol for Repetitive Ventricular Arrhythmia in Patients With Brugada Syndrome,&quot; <i>Eur Heart J</i>, 2006, 27(13):1579-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoproterenol-drug-information/abstract-text/16760208/pubmed\" target=\"_blank\" id=\"16760208\">16760208</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zipes DP, Camm AJ, Borggrefe M, et al, &ldquo;ACC/AHA/ESC 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death),&rdquo; <i>J Am Coll Cardiol</i>, 2006, 48(5):247-346.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/isoproterenol-drug-information/abstract-text/16949478/pubmed\" target=\"_blank\" id=\"16949478\">16949478</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8578 Version 129.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F184870\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F184910\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F184872\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F184892\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F184873\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16160042\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16160043\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F184850\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F184835\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F184853\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Adult\" href=\"#F14472666\" class=\"outlineLink\">Usual Infusion Concentrations: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Usual Infusion Concentrations: Pediatric\" href=\"#F14472667\" class=\"outlineLink\">Usual Infusion Concentrations: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F184851\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726429\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F184919\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F184842\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F184856\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F184839\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299548\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F184844\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F184846\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F7732005\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20680182\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F184848\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F184838\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F184855\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323236\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038663\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8578|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=isoproterenol-patient-drug-information\" class=\"drug drug_patient\">Isoproterenol: Patient drug information</a></li><li><a href=\"topic.htm?path=isoproterenol-pediatric-drug-information\" class=\"drug drug_pediatric\">Isoproterenol: Pediatric drug information</a></li></ul></div></div>","javascript":null}